Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clinic visits. Participation in this study will last approximately 5 years.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• 18 years old or older
• Patient at University of Maryland Baltimore Washington Medical Center
• Willing and able to consent to study procedures listed in the protocol
• Ability to speak and understand English
Locations
United States
Maryland
University of Maryland Baltimore Washington Medical Center
RECRUITING
Glen Burnie
Contact Information
Primary
McKenzie Bedra, MPH
McKenzie.Bedra@umm.edu
410-553-8184
Backup
Jennifer Emel, MA
Jennifer.Emel@umm.edu
410-553-8048
Time Frame
Start Date:2025-03-31
Estimated Completion Date:2032-04
Participants
Target number of participants:750
Treatments
Study Population 1
This study population will consist of individuals who have a new diagnosis of lung cancer and have not received chemotherapy treatment for their lung cancer. Individuals who have received surgical resection or stereotactic body radiation therapy (SBRT) for their lung cancer will be included.
Study Population 2
This study population will consist of individuals who have a diagnosis of lung cancer and have received chemotherapy treatment for their lung cancer. All stages of lung cancer will be included including individuals in remission.
Study Population 3
This study population will consist of individuals who are at high risk of developing lung cancer, such as people with a long smoking history, and are receiving yearly lung screening scans.
Study Population 4
This study population will consist of individuals who may be hospitalized for another condition such as pneumonia or heart failure at time of enrollment into the study. Individuals who have a greater than 10 pack year history of smoking will not be included in this population.
Study Population 5
This study population will consist of individuals who have no other significant medical problems.